Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
Explore this paper's citation graph
Summary
Carrier status for LOF CYP2C19 is associated with an increased risk of adverse clinical events in patients with coronary artery disease on clopidogrel therapy despite differences in clinical significance according to ethnicity.
- Type
- article
- Published
- 2012-08-15
- Cited by
- 106
- References
- 27
- OpenAlex
- https://openalex.org/W22591668
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:31081994
Keywords
Vocational education, Mathematics education, Pedagogy, Apprenticeship, Medical education
References
- Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.
- Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D
- Cytochrome p-450 polymorphisms and response to clopidogrel.
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-Analysis
- Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: A cross‐ethnic comparative study
- Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
- Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
- Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel
- Thrombosis in Coronary Drug-Eluting Stents: Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006*
- Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
- The case for routine genotyping in dual-antiplatelet therapy.
- Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.
- IMPACT OF CYTOCHROME P450 2C19*2 POLYMORPHISM ON THE TARGET LESION OUTCOME AFTER DRUG-ELUTING STENT IMPLANTATION IN JAPANESE PATIENTS RECEIVING CLOPIDOGREL.
- Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
- Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
- Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
- Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
- Measuring inconsistency in meta-analyses
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction
- Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
Cited by
- Pharmacogenomics of oral antiplatelet drugs.
- Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
- Farmakokinetyka kliniczna klopidogrelu i jego metabolitów z uwzględnieniem polimorfizmu genetycznego izoenzymu CYP2C19 i glikoproteiny P
- CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis
- The Pharmacogenetic Control of Antiplatelet Response: Candidate Genes and CYP2C19
- A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism
- Clopidogrel Response Variability: Etiology and Clinical Relevance
- CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel: A Meta-Analysis
- Drug Disposition Alterations in Liver Disease: Extra-hepatic Effects in Cholestasis and Nonalcoholic Steatohepatitis
- Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
- Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
- Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
- Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
- Is personalized medicine a dream or a reality?
- Point-of-Care Platelet Reactivity Determination with VerifyNow-P2Y12 following Administration of Clopidogrel or Prasugrel: Data from a Real-World, Clinical Care Inpatient Setting
- Challenges and Limitations in the Interpretation of Systematic Reviews: Making Sense of Clopidogrel and CYP2C19 Pharmacogenetics
- Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
- Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy
- Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese
Related papers
- Implementation of Project-Based Learning Model and Workforce Character Development for the 21st Century in Vocational High School
- A Preliminary Analysis of Vocational/Academic Integration in Illinois High Schools.
- The Anatomy of a Competency-Based School.
- Student evaluation of a vocational curriculum